Australia · Delayed Price · Currency is AUD Vectus Biosystems Company Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia.
The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis.
Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis.
The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases.
In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.
The company was incorporated in 2005 and is based in Rosebery, Australia.
| Country | Australia |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: 26-34 Dunning Avenue Rosebery, 2018 Australia | |
| Phone | 61 2 8344 1300 |
| Website | vectusbiosystems.com.au |
Stock Details
| Ticker Symbol | VBS |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000VBS9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivan Rajkovic Ph.D. | Interim Chief Technology Officer |
| Robert John Waring BEc, CA, FAICD, FCIS, FFin | Company Secretary |
| Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. | Consultant |